Previous 10 | Next 10 |
CytoDyn ( OTCQB:CYDY -8.8% ) is under early pressure on the heels of a report from STAT's Adam Feuerstein questioning management's motives behind its aggressive promotion of leronlimab for the treatment of COVID-19 patients. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on...
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today anno...
May 1, 2020 Palm Beach, FL – May 1, 2020 – America’s public-private sector collaboration on the global health crisis appears to have borne fruit… very quickly. The government has streamlined regulations and the public sector has responded with unheard o...
April 27th was a big day for CytoDyn ( CYDY ) investors due to the company finally announcing they have submitted the final portion of their BLA to the FDA for leronlimab as a combination therapy with HAART for HIV. What is more, the company publicized leronlimab's branded name, Vyrologix, w...
CytoDyn ( OTCQB:CYDY ) announces results from 49 U.S. COVID-19 patients who received CCR6 antagonist leronlimab under emergency use authorization. Highlights: More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today an...
VANCOUVER, Washington, April 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
Immunonmedics (NASDAQ: IMMU) received regulatory approval from the FDA for Trodelvy (sacituzumab govitecan) for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) for patients that have had at least 2 prior therapies. The PDUFA date was June 2nd so this action is much earlier t...
The top pharmaceutical companies are trying every approach they can imagine to find the weakness in COVID-19’s armor. Pharma companies that were arch enemies are working together. Drugs that are approved for other diseases are being tested as treatments. The front runner is Gilead Scien...
CytoDyn ( OTCQB:CYDY +10.1% ) has completed the rolling submission of its U.S. marketing application seeking approval to use leronlimab, combined with highly active antiretroviral therapy (HAART), in treatment-experienced HIV patients, a Fast Track-tagged indication. More news on: Cyto...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...